
MBA
Honorary Lecturer
- About
-
- Office Address
Office 22a School of Medical Sciences University of Aberdeen Liberty Building Foresterhill AB25 2ZP
- School/Department
- School of Medicine, Medical Sciences and Nutrition
Biography
I currently lead a team of senior scientists at the University of Aberdeen developing shark single chain domains from initial lead isolation through to clinical candidate identification. Having successfully secured substantial pre-commercialisation funding, the focus is to take the lead VNAR domain, E06 (developed as a bio-tool for half-life extension) into the clinic and to strengthen the pipeline portfolio of oncology and anti-inflammatory products. Prior to setting up this team, I was Head of Shark IgNAR Development in Pfizer and Wyeth where I was responsible for establishing robust platforms for the isolation of these binding domains and progressing pipeline candidates. My first experience of developing shark domains was during my time with the antibody engineering spin-out company, Haptogen, where I was Programmes and Alliance manager. I obtained a PhD in biochemistry at the University of Aberdeen and I am currently completing a MBA at Robert Gordon’s University, Business School.
- Research
-
Research Overview
My research very much focuses on early stage biologic drug development from hit generation through to clinical candidate identification exploiting a naturally occurring single chain binding domain known as VNAR. These domains exist naturally in cartilaginous fish and play a role in the adaptive immune system of these animals. As such they can be isolated against specific disease targets both through immunization and semi-synthetic routes of selection. Their small size, high affinity for target, inherent solubility and stability make them very attractive as clinical drug candidates and the team are currently exploiting these attributes to build a strong pipeline portfolio of products.
Current Research
The VNAR Development team:
Senior Scientists:
Dr Marina Kovaleva (ex-Pfizer, Wyeth, Haptogen)
Mr John Steven (ex-Pfizer, Wyeth, Haptogen)
Dr Laura Ferguson (ex-Pfizer)
Dr Nachiket Shembekar
Mohammed Al Qaraghuli (BSc)
PhD Students:
Obinna Ubah
Magdalena Buschhaus
- Publications
-
Page 1 of 1 Results 1 to 28 of 28
Mechanisms of SARS-CoV-2 neutralization by shark variable new antigen receptors elucidated through X-ray crystallography
Nature Communications, vol. 12, no. 1, 7325Contributions to Journals: ArticlesNon-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease
Drug design, development and therapy, vol. 15, pp. 3997-4009Contributions to Journals: Review articlesIn Vitro ELISA and Cell-Based Assays Confirm the Low Immunogenicity of VNAR Therapeutic Constructs in a Mouse Model of Human RA: An Encouraging Milestone to Further Clinical Drug Development
Journal of Immunology Research, vol. 2020, pp. 7283239Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1155/2020/7283239
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/13655/1/Ubah_etal_JImmRes_Invitro_VOR.pdf
- [ONLINE] View publication in Scopus
Uveitis Therapy With Shark Variable Novel Antigen Receptor Domains Targeting Tumor Necrosis Factor Alpha or Inducible T-Cell Costimulatory Ligand
Translational vision science & technology, vol. 8, no. 5, 11Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1167/tvst.8.5.11
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/12970/1/Uveitis_therapy_TVST_Pepple_et_al_VoR.pdf
- [ONLINE] View publication in Scopus
Oriented attachment of VNAR proteins, Q2 via site-selective modification, on PLGA–PEG nanoparticles enhances nanoconjugate performance
Chemical Communications, vol. 55, no. 53, pp. 7671-7674Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1039/c9cc02655j
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/12481/2/Oriented_attachment_of_VNAR_proteins_Final.pdf
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/12481/1/Supplementary_Information.pdf
- [ONLINE] http://xlink.rsc.org/?DOI=C9CC02655J
- [ONLINE] View publication in Mendeley
- [ONLINE] View publication in Scopus
An Anti-hTNF-α Variable New Antigen Receptor Format Demonstrates Superior in vivo Preclinical Efficacy to Humira® in a Transgenic Mouse Autoimmune Polyarthritis Disease Model
Frontiers in Immunology, vol. 10, 526Contributions to Journals: ArticlesNext-generation flexible formats of VNAR domains expand the drug platform’s utility and developability
Biochemical Society Transactions, vol. 46, no. 6, pp. 1559-1565Contributions to Journals: Review articles- [ONLINE] DOI: https://doi.org/10.1042/BST20180177
- [ONLINE] View publication in Scopus
Novel, Anti-hTNF-α Variable New Antigen Receptor Formats with Enhanced Neutralising Potency and Multifunctionality, Generated for Therapeutic Development
Frontiers in Immunology, vol. 8, 1780Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.3389/fimmu.2017.01780
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/9849/1/fimmu_08_01780.pdf
Phage Display Derived IgNAR V Region Binding Domains for Therapeutic Development
Current Pharmaceutical Design, vol. 22, no. 43, pp. 6519-6526Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.2174/1381612822666160907091708
VNARs: An Ancient and Unique Repertoire of Molecules That Deliver Small, Soluble, Stable and High Affinity Binders of Proteins
Antibodies, vol. 4, no. 3, pp. 240-258Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.3390/antib4030240
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/4967/1/antibodies_04_00240.pdf
Structural insights and biomedical potential of IgNAR scaffolds from sharks
mAbs, vol. 7, no. 1, pp. 15-25Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.4161/19420862.2015.989032
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/4199/1/19420862.2015.pdf
ISOLATION OF THERAPEUTIC TARGET SPECIFIC VNAR DOMAINS TO ICOSL
Patents: PatentsShark variable new antigen receptor biologics: a novel technology platform for therapeutic drug development
Expert opinion on biological therapy, vol. 14, no. 10, pp. 1527-1539Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1517/14712598.2014.937701
SINGLE DOMAIN BINDING MOLECULE
Patents: PatentsAtypical antigen recognition mode of a shark immunoglobulin new antigen receptor (IgNAR) variable domain characterized by humanization and structural analysis
The Journal of Biological Chemistry, vol. 288, no. 24, pp. 17408-17419Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1074/jbc.M112.435289
Generation and isolation of target-specific single-domain antibodies from shark immune repertoires
Methods in Molecular Biology: Antibody Engineering. Chames, P. (ed.). Humana Press, pp. 177-194, 18 pagesChapters in Books, Reports and Conference Proceedings: Chapters- [ONLINE] DOI: https://doi.org/10.1007/978-1-61779-974-7_9
Characterization of the immunoglobulin repertoire of the spiny dogfish (Squalus acanthias)
Developmental and Comparative Immunology, vol. 36, no. 4, pp. 665-679Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.dci.2011.10.007
Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain
mAbs, vol. 4, no. 6, pp. 673-685Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.4161/mabs.22242
Shark novel antigen receptors: the next generation of biologic therapeutics?
Pharmaceutical Biotechnology. Guzman, C. A., Feuerstein, G. Z. (eds.). Springer, pp. 49-62, 14 pagesChapters in Books, Reports and Conference Proceedings: Chapters- [ONLINE] DOI: https://doi.org/10.1007/978-1-4419-1132-2_6
Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy
Hepatology International, vol. 2, no. 4, pp. 405-15Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1007/s12072-008-9093-y
Azole antifungals induce up-regulation of SAP4, SAP5 and SAP6 secreted proteinase genes in filamentous Candida albicans cells in vitro and in vivo
Journal of Antimicrobial Chemotherapy, vol. 61, no. 2, pp. 315-322Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1093/jac/dkm456
Niche-specific regulation of central metabolic pathways in a fungal pathogen
Cellular Microbiology, vol. 8, no. 6, pp. 961-971Contributions to Journals: ArticlesCandida albicans VAC8 is required for vacuolar inheritance and normal hyphal branching
Eukaryotic Cell, vol. 5, no. 2, pp. 359-367Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1128/EC.5.2.359-367.2006
Exposure of Candida albicans to antifungal agents affects expression of SAP2 and SAP9 secreted proteinase genes
Journal of Antimicrobial Chemotherapy, vol. 55, no. 5, pp. 645-654Contributions to Journals: Articles- [ONLINE] http://jac.oxfordjournals.org/content/55/5/645
- [ONLINE] DOI: https://doi.org/10.1093/jac/dki088
GFP as a quantitative reporter of gene regulation in Candida albicans
Yeast, vol. 21, no. 4, pp. 333-340Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1002/yea.1099
CIp10, an efficient and convenient integrating vector for Candida albicans
Yeast, vol. 16, no. 4, pp. 325-327Contributions to Journals: ArticlesGene regulation during morphogenesis in Candida albicans
Dimorphism in Human Pathogenic and Apathogenic Yeasts. Ernst, J., Schmidt, A. (eds.). Karger, pp. 112-125, 14 pagesChapters in Books, Reports and Conference Proceedings: Chapters- [ONLINE] DOI: https://doi.org/10.1159/000060347
Evidence for an active fibrinolytic system in normal human bone marrow
British Journal of Haematology, vol. 93, no. 1, pp. 170-6Contributions to Journals: Articles